These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15609792)

  • 1. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer.
    Lejeune C; Arveux P; Dancourt V; Béjean S; Bonithon-Kopp C; Faivre J
    Int J Technol Assess Health Care; 2004; 20(4):434-9. PubMed ID: 15609792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
    Sonnenberg A; Delcò F; Inadomi JM
    Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy.
    O'Leary BA; Olynyk JK; Neville AM; Platell CF
    J Gastroenterol Hepatol; 2004 Jan; 19(1):38-47. PubMed ID: 14675241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of screening for colorectal cancer in the general population.
    Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
    JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test.
    Lejeune C; Dancourt V; Arveux P; Bonithon-Kopp C; Faivre J
    Int J Technol Assess Health Care; 2010 Jan; 26(1):40-7. PubMed ID: 20059779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
    Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
    Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
    Wong CK; Lam CL; Wan YF; Fong DY
    BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis.
    Ladabaum U; Chopra CL; Huang G; Scheiman JM; Chernew ME; Fendrick AM
    Ann Intern Med; 2001 Nov; 135(9):769-81. PubMed ID: 11694102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for colorectal cancer: current status in Japan.
    Saito H
    Dis Colon Rectum; 2000 Oct; 43(10 Suppl):S78-84. PubMed ID: 11052482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.
    Wu GH; Wang YM; Yen AM; Wong JM; Lai HC; Warwick J; Chen TH
    BMC Cancer; 2006 May; 6():136. PubMed ID: 16723013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria.
    Jahn B; Sroczynski G; Bundo M; Mühlberger N; Puntscher S; Todorovic J; Rochau U; Oberaigner W; Koffijberg H; Fischer T; Schiller-Fruehwirth I; Öfner D; Renner F; Jonas M; Hackl M; Ferlitsch M; Siebert U;
    BMC Gastroenterol; 2019 Dec; 19(1):209. PubMed ID: 31805871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Colorectal Cancer Screening Interventions with Their Effects on Health Disparity Being Considered.
    Lee KS; Park EC
    Cancer Res Treat; 2016 Jul; 48(3):1010-9. PubMed ID: 26727714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance.
    Vijan S; Hwang EW; Hofer TP; Hayward RA
    Am J Med; 2001 Dec; 111(8):593-601. PubMed ID: 11755501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy.
    Sobhani I; Alzahouri K; Ghout I; Charles DJ; Durand-Zaleski I
    Dis Colon Rectum; 2011 Jul; 54(7):876-86. PubMed ID: 21654256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness and projected national impact of colorectal cancer screening in France.
    Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G
    Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential impact of population-based colorectal cancer screening in Canada.
    Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
    Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal occult blood testing for colorectal cancer: a perspective.
    Barry MJ
    Ann Oncol; 2002 Jan; 13(1):61-4. PubMed ID: 11863113
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.